Navigation Links
Emory Eye Center Implants Its First Retinal Chips In Patients With Retinitis Pigmentosa

An expanded clinical trial conducted by Optobionics Corporation involving the implantation of a retina mircrochip has allowed Emory Eye Center and the Atlanta Veterans Affairs Rehabilitation Research & Development Center to implant the device in several patients. The patients all have retinitis pigmentosa with moderate-to-severe vision loss. Three centers in the United States have been chosen to conduct the expanded trial. Other than Emory and the VA Rehabilitation R&D Center they include Rush University Medical Center's Department of Ophthalmology and the Wilmer Eye Institute at Johns Hopkins Medical Center.

Retinitis pigmentosa is a pathologic condition that is hereditary and causes progressive retinal degeneration in both eyes. It is a general term for a number of diseases that predominantly affect the photoreceptor layer or "light sensing" cells of the retina. Night blindness develops, usually in childhood, followed by loss of peripheral visual field, progressing over many years to tunnel vision and finally blindness.

At Emory Eye Center retina specialists Thomas M. Aaberg, Sr. and Jiong Yan performed the surgery recently on five patients. Another two patients are planned for mid-February.

"This experimental device may make it possible for those with retinitis pigmentosa to have a much better quality of life," says Dr. Aaberg. "We are excited to be able to participate in this clinical trial as part of Emory Eye Center's ongoing research and surgical procedures to fight blinding eye disease. Because Emory and the Atlanta VA Rehabilitation R&D Center met the FDA and Optobionics criteria that included surgical expertise, a strong research component and an established patient base of degenerative retinal diseases, we were able to be a part of this important study."

Pre- and post-surgery patients are evaluated by a team of researchers working at the Eye Center and the VA Rehabilitation R&D Center including Ronald A. Schu chard, PhD and Claire Barnes, PhD.

"This clinical trial will help evaluate the potential of Optobionics' ASR® device to provide improved functional vision or to at least slow down the progressive vision loss" says Dr. Schuchard, principal investigator for the project. "There are very few vision rehabilitative options for patients with retinal degenerative diseases, so the opportunity to be part of evaluating an experimental rehabilitative intervention for these patients is very exciting."


'"/>

Source:Emory University Health Sciences Center


Related biology news :

1. Emory Study Tests Bone Marrow Stem Cells to Improve Circulation in Legs
2. Fox Chase Cancer Center scientists identify immune-system mutation
3. Massey Cancer Center researcher helps to identify a piece of the cancer puzzle
4. $6.5 Million Grant for Microarray Center at Yale School of Medicine
5. Woods Hole Research Center plans controlled burn in Amazon rainforest
6. VCU Massey Cancer Center study shows enzyme linked to spread of breast cancer cells
7. Center releases new public survey on stem cells
8. World Trade Center identifications pushed forensic DNA technology
9. VCU Massey Cancer Center researchers identify a new class of anti-cancer drugs based on platinum
10. Mayo Clinic Cancer Center: Harnessing the measles virus to attack cancer
11. Timing is everything: First step in protein building revealed
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/31/2016)... , March 31, 2016  Genomics firm Nabsys ... founding CEO, Barrett Bready , M.D., who returned ... of the original technical leadership team, including Chief Technology ... of Product Development, Steve Nurnberg and Vice President of ... to the company. Dr. Bready served as ...
(Date:3/23/2016)... WAKEFIELD, Massachusetts , March 23, 2016 ... kombiniert im Interesse erhöhter Sicherheit Gesichts- und ... Xura, Inc. (NASDAQ: MESG ... heute bekannt, dass das Unternehmen mit SpeechPro ... insbesondere aus der Finanzdienstleistungsbranche, wird die Möglichkeit ...
(Date:3/22/2016)... OTTAWA, Ontario , PROVO ... 2016 Newborn Screening Ontario (NSO), which operates ... for molecular testing, and Tute Genomics and ... process management technology respectively, today announced the launch of ... new next-generation sequencing (NGS) testing panel. ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... , ... June 24, 2016 , ... Researchers at the ... commonly-identified miRNAs in people with peritoneal or pleural mesothelioma. Their findings are the subject ... it now. , Diagnostic biomarkers are signposts in the blood, lung fluid or ...
(Date:6/23/2016)... , June 23, 2016 A person commits ... the crime scene to track the criminal down. ... U.S. Food and Drug Administration (FDA) uses DNA evidence to ... Sound far-fetched? It,s not. The FDA has ... to support investigations of foodborne illnesses. Put as simply as ...
(Date:6/23/2016)... FRANCISCO , June 23, 2016   EpiBiome ... has secured $1 million in debt financing from Silicon ... ramp up automation and to advance its drug development ... its new facility. "SVB has been an ... beyond the services a traditional bank would provide," said ...
(Date:6/23/2016)... June 23, 2016  Blueprint Bio, a company dedicated ... the medical community, has closed its Series A funding ... . "We have received a commitment from ... we need to meet our current goals," stated ... the runway to complete validation on the current projects ...
Breaking Biology Technology: